Security key
18978H508
CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CUSIP: 18978H508
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 280,434
- Total 13F value
- $1,340,474
- Share change
- +134,838
- SEC-reported price per share
- $4.78
- Number of holders
- 11
- Value change
- +$699,729
- Number of buys
- 6
- Number of sells
- 6
- Shares outstanding
- 1,487,778
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
11
Top holders
10
CNSP full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
CNS Pharmaceuticals, Inc. SEC filings
CNS Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 18978H508
Recent filing periods:
Ownership snapshot
Top reported holders of CNSP - CNS Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
13/15
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
2 rows are not safely comparable across share classes.
13D/G row: Ikarian Capital, LLC
Showing 1-6 of 15 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 9.9%.
13 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
9.9%
Stonepine Capital Management, LLC
9.9%
ARMISTICE CAPITAL, LLC
5%
Michal Fisher
0.13%
GEODE CAPITAL MANAGEMENT, LLC
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
Company
|
9.9%
|
$749,706
147,290 shares
|
+$516,431 | 30 Jun 2026 |
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
9.9%
|
$402,671
159,790 shares
|
+$279,627 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$5,432
30,177 shares
|
-$95,575 | 30 Sep 2025 |
| Michal Fisher |
3/4/5
Director
|
0.13%
|
$10,000
2,000 shares
|
+$10,000 | 18 May 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.6%
|
$55,653
23,189 shares
|
— | 31 Mar 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
Company
|
0.91%
|
$32,322
13,524 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
11
Shares
280,434
Rows available
11
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
11
Q2 2026 holders
11
Holder diff
0
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend